Comparative effectiveness of palliative chemotherapy versus neoadjuvant chemotherapy followed by radical cystectomy versus cystectomy followed by adjuvant chemotherapy versus cystectomy for regional node-positive bladder cancer: A retrospective analysis: KCSG GU 17-03

Woo Kyun Bae | Hyo Jin Lee | Se Hoon Park | Jung Hoon Kim | Hee Jun Kim | Chi Hoon Maeng | Inkeun Park | Byeong Seok Sohn | Jung A. Kim | Kyung Hee Lee | Do Hyoung Lim | Hyun Chang | Sung Min Kim | Ho Young Kim | Hunho Song | Seungtaek Lim | Jae Ho Byun | Hyun Ae Jung

1Department of Hemato-Oncology, Chonnam National University Medical School, Gwangju, Republic of Korea
2Department of Internal Medicine, Chungnam National University College of Medicine, Daejeon, Republic of Korea
3Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea
4Department of Hemato-Oncology, Gyeongsang National University hospital, Jinju, Republic of Korea
5Department of Internal Medicine, Chung-Ang University College of Medicine, Seoul, Korea
6Division of Medical Oncology-Hematology, Department of Medicine, College of Medicine, Kyung Hee University Hospital, Seoul, Republic of Korea
7Division of Medical Oncology, Department of Internal medicine, Gachon University Gil Medical Center, Incheon, Republic of Korea
8Department of Internal Medicine, Inje University Sanggye Paik Hospital, Seoul, Republic of Korea
9Division of Medical Oncology-Hematology, Department of Medicine, College of Medicine, Kangdong Kyung Hee University Hospital, Seoul, Republic of Korea
10Department of Hemato-Oncology, College of Medicine, Yeungnam University, Daegu, Republic of Korea
11Department of Hemato-Oncology, Dankook University Hospital, Cheonan, Republic of Korea
12Department of Medical Oncology, Catholic Kwandong University International St. Mary's Hospital, Incheon, Republic of Korea
13Division of Hematology-Oncology, Department of Medicine, Samsung Changwon, Sungkyunkwan University School of Medicine, Changwon, Korea
14Department of Internal Medicine, College of Medicine, Hallym University Medical Center, Hallym University, Anyang, Korea
15Department of Internal Medicine, College of Medicine, Kangdong Sacred Heart Hospital, Hallym University, Seoul, South Korea
16Department of Internal Medicine, Wonju Severance Christian Hospital, Wonju, Korea
17Division of Oncology, Department of Internal Medicine, Incheon St. Mary's Hospital, The Catholic University of Korea, Incheon, Korea

Abstract
The regional lymph node-positive bladder cancer was classified as stage IV in the AJCC 7th edition but was changed to stage IIIIB in the 8th edition, revised in 2018. Among the various studies involving immune checkpoint inhibitors, groups that had...
The treatment for node-positive bladder cancer, diagnosed using lymph node biopsy or image, is chemotherapy or chemotherapy combined with radiotherapy, in accordance with the NCCN and ESMO guidelines. Cisplatin combination chemotherapy such as gemcitabine and cisplatin (GP) or methotrexate, vinblastine, adriamycin, and cisplatin (MVAC) for node-positive bladder cancer. MVAC has several side effects, including marrow suppression and mucositis, but is better tolerated in combination with G-CSF. However, long-term survival rates for locally advanced (ie, with extravesical and/or node-positive disease) and metastatic disease remain dismal, with an overall survival (OS) of 9-15 months and a 5-year OS rate of 5% for the latter, even with the standard of care platinum-based chemotherapy. In a population-based study of patients with lymph node metastases, among 1739 patients with bladder cancer presenting lymph node involvement only 36.5% of patients received palliative chemotherapy. In a study from SEER data among 5201 patients who received cystectomy with lymphadenectomy for bladder cancer, 1260 (24.3%) patients had regional lymph nodes. Patients with lymph node metastases have an overall 5-year survival rate of 31% after radical cystectomy. The number of lymph nodes removed at the time of cystectomy is associated with improved survival. In current clinical practice, although palliative chemotherapy is the standard of treatment, cystectomy with or without lymphadenectomy is frequently performed for lymph node-positive bladder cancer. The evidence of efficacy of neoadjuvant and adjuvant chemotherapy for treating bladder cancer after cystectomy is lacking because most neoadjuvant trials include patients with lymph node-negative muscle-invasive bladder cancer. Adjuvant cisplatin-based chemotherapy is supported by a recent a large cohort analysis, but the results of this study are controversial.

There were two randomized trials of first-line immune checkpoint inhibitors in untreated metastatic urothelial cell cancer. In a recent study using pembrolizumab as the first-line treatment against cisplatin-ineligible patients with locally advanced and unresectable or metastatic urothelial cell cancer, among 370 patients, 14% of them showed lymph node-only metastasis and showed 47% of objective response rate. In a study of atezolizumab administered to 119 patients, 26% of them had lymph node-only metastasis and showed a 32% objective response rate.

In the AJCC 7th edition, lymph node metastasis is classified into stage IV, regardless of the degree or number of metastasis. Recently, the AJCC 8th edition revised in 2018, T1a-T4a, N1, and M0 tumors were changed to stage IIIA and T1a-T4a, N2-N3, and M0 tumors were changed to stage IIIB. Previously, the group referred to as stage IV lymph...
node-positive bladder cancer was divided into stage IIIA and stage IIIB.

As the biology of regional lymph node-positive bladder cancer differs from that of metastatic bladder cancer and the classification of lymph node metastasis has recently changed, it is necessary to reconsider the best treatment strategy. Clinical data from various treatment strategies for treating regional lymph node-positive bladder cancer are available. We have very few clinical available data comparing treatment outcomes for regional lymph node-positive bladder cancer. Therefore, comparing the effectiveness of different treatment strategies, using chemotherapy, surgery, or a combination of the two is of critical importance. We performed a comparative analysis of four treatment strategies in regional lymph node-positive bladder cancer: palliative chemotherapy, neoadjuvant chemotherapy followed by cystectomy, cystectomy followed by adjuvant chemotherapy, and cystectomy alone.

2 | MATERIALS AND METHODS

2.1 | Study subjects and data collection

This study is a multicenter, retrospective study that included patients with histologically confirmed urothelial cell carcinoma in bladder ranging from 2010 to 2015. This study was performed at 16 centers in South Korea. According to AJCC 7th stage classification criteria, they were all T, N1-3, M0 tumors. The definition of regional positive lymph node is >1.5 cm as seen in an abdomen-pelvis CT or MRI and located in the true pelvis or in the common iliac. Patients were older than 20 years and received one of the following four treatments: (a) palliative chemotherapy; (b) preoperative chemotherapy followed by radical cystectomy; (c) radical cystectomy followed by adjuvant chemotherapy; or (d) radical cystectomy.

2.2 | Statistical analysis

All data cutoff for the analysis was 30 June 2018. To compare treatment patterns, patients were divided according to the clinical nodal stage and the chi-squared test was used. The OS curve was calculated using the Kaplan-Meier estimator and compared using the log rank test. OS is presented in all figures and tables as median values and two-sided 95% confidence intervals (CIs). OS was defined as the first date of diagnosis until death resulting from any cause. Data were analyzed using SPSS-19 (IBM SPSS Statistics, Inc).

2.3 | Ethics statement

The protocol was approved by the Protocol Review Committee of the Korean Cancer Study Group (KCSG GU 17-03) and by the Institutional Review Board at each participating institute. The trial was conducted in accordance with the Declaration of Helsinki.

3 | RESULTS

3.1 | Patient characteristics

During the study period, 230 patients diagnosed with regional lymph node-positive bladder cancer from 18 member institutions of the Korean Cancer Study Group were included. During the study period, 44 patients received palliative chemotherapy, 30 received neoadjuvant chemotherapy followed by radical cystectomy, 129 received radical cystectomy followed by adjuvant chemotherapy, and 27 received radical cystectomy only (Table 1). According to the AJCC 7th edition stage classification criteria, 100 patients were N1 stage and 130 patients were N2-N3 stage. For the neoadjuvant chemotherapy, 28 patients received...
the GP regimen, one patient received the MVAC regimen, and another received the cisplatin, methotrexate, and vinblastine (CMV) regimen. The median cycle of neoadjuvant chemotherapy before radical cystectomy was 2 (range: 1-4). For adjuvant chemotherapy, all patients received GP, and the median cycle of chemotherapy was 3 (range: 1-7). For first-line palliative chemotherapy, 42 patients received GP, one patient received CMV regimen, and another received MVAC regimen.

3.2 | Treatment patterns by nodal stage

We evaluated treatment patterns dividing the patients by nodal stage (Table 2). In patients who had N1 stage, 8.0%, 19.0%, 62.0%, and 11.0% received palliative chemotherapy, neoadjuvant chemotherapy followed by radical cystectomy, radical cystectomy followed by adjuvant chemotherapy, and radical cystectomy only, respectively, while in the N2-N3 group, the percentages were 27.6%, 8.7%, 51.2%, and 12.6%, respectively.

3.3 | Overall survival by treatment

The median OS for regional lymph node-positive bladder cancer was 30.4 months (95% CI [lower-upper], 25.3-35.6). The median OS were 19.3 months (95% CI, 17.3-24.3) for palliative chemotherapy, 49.1 months (95% CI, 20.7-77.5) for neoadjuvant chemotherapy followed by radical cystectomy, 42.6 months (95% CI, 32.0-53.2) for radical cystectomy followed by adjuvant chemotherapy, and 11.2 months (95% CI, 25.2-35.6) for radical cystectomy only ($P < .001$) (Figure 1).

3.4 | Overall survival by N stage

The median OS was 42.6 months (95% CI, 33.9-51.3) for the N1 stage versus 21.3 months (95% CI, 16.9-25.7) for the N2-N3 stage in bladder cancer ($P = .004$) (Figure 2). In the group with N1 stage, the median OS was 21.0 months for palliative chemotherapy, 49.1 months for neoadjuvant chemotherapy followed by radical cystectomy, 45.9 months for radical cystectomy followed by adjuvant chemotherapy, and 16.0 months for radical cystectomy only ($P < .001$) (Figure 3A). In the group with N2-N3 stage, the median OS was 19.0 months for palliative chemotherapy, 27.7 months for neoadjuvant chemotherapy followed by radical cystectomy, 33.0 radical cystectomy followed by adjuvant chemotherapy, and 11.0 months for radical cystectomy only ($P < .001$) (Figure 3B).

4 | DISCUSSION

The aim of this study was to compare different treatment strategies for regional lymph node-positive bladder cancer with the aim of understanding the current clinical treatment patterns. While radical cystectomy for lymph node-positive
bladder cancer is possible, our results showed that neoadjuvant chemotherapy followed by radical cystectomy or radical cystectomy followed by postoperative chemotherapy is superior in terms of OS.

In 2016, there were 4361 new cases of bladder cancer in Korea. In a previous clinical trial of stage IV bladder cancer, the proportion of patients with any T, N1-N3, M0 tumor grade was about 15%. Several guidelines indicated that palliative chemotherapy is the standard of treatment for regional lymph node-positive bladder cancer. If tumor shrinkage is noted following the chemotherapy, radical cystectomy could be considered. Until now, no study has focused on the treatment outcome in regional lymph node-positive bladder cancer. This type of cancer has been treated in the clinic on the basis of a previous study of muscle-invasive bladder cancer. Recently, radical cystectomy with extended lymphadenectomy has been considered for curative intent for regional lymph node-positive bladder cancer. However, the surgery-only strategy showed poor outcomes and there was no study outcomes on neoadjuvant chemotherapy followed by radical cystectomy. Only muscle-invasive and lymph node-negative bladder cancer shows sensitivity to neoadjuvant chemotherapy. Among our groups, 30 patients who received neoadjuvant chemotherapy followed by radical cystectomy showed the most favorable OS.

In bladder cancer, the knowledge of tumor biology and somatic alterations could lead to the discovery of novel therapeutic targets, such as the recently developed immune checkpoint inhibitors. According to AJCC 7th edition classification criteria, bladder cancer with regional lymph node involvement was considered at stage IV, and thus surgery was not indicated. However, recent retrospective data showed favorable outcome for regional lymph node-positive bladder cancer treated with surgery, and several surgeons perform radical cystectomy rather than administer the suggested palliative chemotherapy. New surgical techniques, such as extended lymphadenectomy including cephalad boundary at the aortic bifurcation or take off from the inferior mesenteric artery, which showed better outcomes were recently developed. In a study of immune checkpoint inhibitors, patients who had only regional lymph node metastasis showed better outcomes than those with distant metastasis, but these groups presented tumors with different biological origins (urothelial cancer).
In a previous observation cohort study, subsets of patients with regional lymph node-positive bladder cancer showed durable disease control and long-term survival. Moreover, compared to single modality including palliative chemotherapy or surgery alone, combined modality treatments showed better outcomes.

However, it is important to point out that this study has some limitations. The retrospective nature and observational study design lead to drawbacks including potential selection bias and unmeasured confounders, such as performance status indicator or other organ function parameters. In practice, the patients selected for combined radical cystectomy and chemotherapy would be generally fitter than the patients selected for palliative chemo or cystectomy only.

Patients who received concurrent chemoradiotherapy (CCRT) for bladder cancer were excluded. In bladder cancer, CCRT could be considered as bladder preservation treatment in node-negative case if patients refused radical cystectomy or were not eligible for radical cystectomy. In a multicenter, randomized, phase three trial, combined CCRT showed better locoregional control than did radiotherapy alone for node-negative, muscle-invasive bladder cancer. Chemoradiotherapy after transurethral resection of muscle-invasive, node-negative bladder cancer showed 72% complete response, 64% of 10-year local control, and 42% of 10-year disease-specific survival.

In clinical practice, as physicians encounter patients with bladder cancer of varying stages, a multidisciplinary approach for the initial diagnosis could be advised and a combined therapy strategy for the treatment of regional lymph node-positive bladder cancer should be considered.

This study showed that a combined therapy strategy to treat regional lymph node-positive bladder cancer had better outcomes than those of single therapy strategy. For example, radical cystectomy followed by adjuvant chemotherapy compared with radical cystectomy alone showed better outcomes.

To determine the optimal sequence for the combined therapy that includes chemotherapy and radical cystectomy, this study included 30 patients who received neoadjuvant chemotherapy followed by radical cystectomy and 127 patients who received radical cystectomy followed by adjuvant chemotherapy. If the extent of regional lymph node-positive bladder cancer was ineligible for radical cystectomy initially, after at least two cycles of chemotherapy, reevaluation for radical cystectomy could be considered, according to the combined therapy approach. However, due to the small number of patients included in neoadjuvant chemotherapy, the comparison to the adjuvant group directly was limited.

5 | CONCLUSIONS

Combined modality with radical cystectomy with perioperative chemotherapy showed better outcomes than single therapy strategies for regional lymph node-positive bladder cancer. In this study, we also tried to find subsets of patients who were feasible to be treated with a combined therapy approach, using a multidisciplinary approach at initial diagnosis and during treatment.

ACKNOWLEDGMENTS

The research was supported (in part) by the Korean Cancer Study Group. This study was supported by a grant from the National R&D Program for Cancer Control, Ministry of Health and Welfare, Republic of Korea (1720150).

CONFLICT OF INTEREST

None declared.

ORCID

Inkeun Park https://orcid.org/0000-0003-3064-7895
Hyun Ae Jung https://orcid.org/0000-0002-1583-4142

REFERENCES

1. Bellmunt J, Orsola A, Leow JJ, Wiegel T, De Santis M, Horwich A. Bladder cancer: ESMO practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2014;25(suppl 3):iii40‐iii48.
2. von der Maase H, Sengelov L, Roberts JT, et al. Long-term survival results of a randomized trial comparing gemcitabine plus cisplatin, with methotrexate, vinblastine, doxorubicin, plus cisplatin in patients with bladder cancer. J Clin Oncol. 2005;23:4602-4608.
3. De Santis M, Bellmunt J, Mead G, et al. Randomized phase II/III trial assessing gemcitabine/carboplatin and methotrexate/carboplatin/vinblastine in patients with advanced urothelial cancer who are unfit for cisplatin-based chemotherapy: EORTC study 30986. J Clin Oncol. 2012;30:191-199.
4. Bellmunt J, von der Maase H, Mead GM, et al. Randomized phase III study comparing paclitaxel/cisplatin/gemcitabine and gemcitabine/cisplatin in patients with locally advanced or metastatic urothelial cancer without prior systemic therapy: EORTC Intergroup Study 30987. J Clin Oncol. 2012;30:1107-1113.
5. Galsky MD, Stensland K, Sfakianos JP, et al. Comparative effectiveness of treatment strategies for bladder cancer with clinical evidence of regional lymph node involvement. J Clin Oncol. 2016;34:2627-2635.
6. Wright JL, Lin DW, Porter MP. The association between extent of lymphadenectomy and survival among patients with lymph node metastases undergoing radical cystectomy. Cancer. 2008;112:2401-2408.
7. Grossman HB, Natale RB, Tangen CM, et al. Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer. N Engl J Med. 2003;349:859-866.
8. Kitamura H, Tsukamoto T, Shibata T, et al. Randomised phase III study of neoadjuvant chemotherapy with methotrexate, doxorubicin, vinblastine and cisplatin followed by radical cystectomy compared with radical cystectomy alone for muscle-invasive bladder cancer.
cancer: Japan Clinical Oncology Group Study JCOG0209. Ann Oncol. 2014;25:1192-1198.

9. Sherif A, Holmberg L, Rintala E, et al. Neoadjuvant cisplatinum based combination chemotherapy in patients with invasive bladder cancer: a combined analysis of two Nordic studies. Eur Urol. 2004;45:297-303.

10. Sternberg CN, Bellmunt J, Sonpavde G, et al. ICUD-EAU International consultation on bladder cancer 2012: chemotherapy for urothelial carcinoma-neoadjuvant and adjuvant settings. Eur Urol. 2013;63:58-66.

11. Balar AV, Galsky MD, Rosenberg JE, et al. Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial. Lancet. 2017;389:67-76.

12. Balar AV, Castellano D, O'Donnell PH, et al. First-line pembrolizumab in cisplatin-ineligible patients with locally advanced and unresectable or metastatic urothelial cancer (KEYNOTE-052): a multicentre, single-arm, phase 2 study. Lancet Oncol. 2017;18:1483-1492.

13. Jung K-W, Won Y-J, Kong H-J, Lee ES. Cancer statistics in Korea: incidence, mortality, survival, and prevalence in 2016. Cancer Res Treat. 2019;51:417-430.

14. Choi W, Porten S, Kim S, et al. Identification of distinct basal and luminal subtypes of muscle-invasive bladder cancer with different sensitivities to frontline chemotherapy. Cancer Cell. 2014;25:152-165.

15. Damrauer JS, Hoadley KA, Chism DD, et al. Intrinsic subtypes of high-grade bladder cancer reflect the hallmarks of breast cancer biology. Proc Natl Acad Sci USA. 2014;111:3110-3115.

16. James ND, Hussain SA, Hall E, et al. Radiotherapy with or without chemotherapy in muscle-invasive bladder cancer. N Engl J Med. 2012;366:1477-1488.

17. Rödel C, Grabenbauer GG, Kühn R, et al. Combined-modality treatment and selective organ preservation in invasive bladder cancer: long-term results. J Clin Oncol. 2002;20:3061-3071.

How to cite this article: Bae WK, Lee HJ, Park SH, et al. Comparative effectiveness of palliative chemotherapy versus neoadjuvant chemotherapy followed by radical cystectomy versus cystectomy followed by adjuvant chemotherapy versus cystectomy for regional node-positive bladder cancer: A retrospective analysis: KCSG GU 17-03. Cancer Med. 2019;8:5431-5437. https://doi.org/10.1002/cam4.2446